Lung Therapeutics: Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions

(marketscreener.com) Taiho Pharmaceutical Co., Ltd, and Lung Therapeutics, Inc. announced today an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions, for the territory of Japan. This press release features multimedia. View the full release...https://www.marketscreener.com/news/latest/Taiho-and-Lung-Therapeutics-Enter-Into-an-Exclusive-License-Agreement-in-Japan-for-LTI-01-Treatment--31760565/?utm_medium=RSS&utm_content=20201112